Nxera Pharma

Today we shared our financial results and operational activities for the first quarter of 2024. We have had a strong start to the year, positioning us for the next stage of our journey to become a leading biopharmaceutical company in Japan. Read the full announcement here: https://lnkd.in/ef3xEY7S #FinancialResults

NBI-1117568, our partnered M4 receptor agonist being advanced in Phase 2 clinical trials by Neurocrine Biosciences for the treatment of schizophrenia and other neuropsychiatric disorders, has successfully completed a long-term preclinical toxicity program, triggering a $15 million payment to Nxera from Neurocrine Biosciences.   This important safety development milestone meets US FDA requirements to allow for safe, chronic dosing in future clinical trials.   Read more here: https://lnkd.in/eHtsfMnn

We’re pleased to share that we have entered into an exclusive supply and distribution agreement with HANDOK to commercialize PIVLAZ™ in South Korea. PIVLAZ™ is the first drug approved in South Korea for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage (aSAH). Read more here: https://lnkd.in/eAdxcD_K

  WODA expands its reach to Japan and South Korea 🌏 with the addition of Nxera Pharma (formerly known as Sosei Heptares)!   We are delighted that this technology-powered biopharma company, renowned for its world-class drug design capabilities and highly experienced clinical development and commercialization teams, will represent the Alliance in Japan and South Korea.   💬 Chris Cargill, President & CEO of Nxera Pharma: “People with rare or orphan diseases in Japan and South Korea deserve better access to effective, life-changing medicines. At Nxera Pharma, we are committed to delivering this and I am confident that being part of this global alliance will support our collective mission to provide the best new therapies to patients in need.” #WODAalliance #NewMembers #Japan #SouthKorea #OprhanDrugs

We are pleased to share that Nxera has joined the World Orphan Drug Alliance (WODA), a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in complex markets around the world. Nxera will represent WODA in Japan and South Korea.   The Alliance consists of 12 member companies and provides access to approximately 200 million rare disease patients across 156 countries.   Learn more: https://lnkd.in/eqTTRhB8

Nxera’s mission is clear: to accelerate the development of life-changing medicines, by investing in cutting-edge science and technology. This will help us achieve our vision, to lead the next era of medicine. From Japan, for Japan, and the world. Learn more: https://www.nxera.life/

Our life’s work, is life itself. We’re not just launching a bold new brand and identity; we’re unveiling a powerful new biopharma company for Japan and the world beyond. The next era for medicine has arrived. Visit our new website: https://www.nxera.life

Nxera Pharma is the new name for Sosei Heptares. Derived from the words ‘Next’ and ‘Era’, our new name embodies our commitment to lead the way in the Next Era of medicine. We're on a mission to pioneer life-changing medicines, driven by world-leading science, from Japan, for Japan, and by extension, to the world. Enter the Next Era: https://www.nxera.life

Our neuroscience Program Leader, Clíona MacSweeney, was featured on Labiotech.eu’s Beyond Biotech podcast discussing the latest drug development trends in schizophrenia.   Clíona discussed what the schizophrenia treatment landscape looks like (including serotonin and dopamine modulation, muscarinic modulators, excitatory and inhibitory tone, digital therapeutic and epigenetic modulation), why 2024 is shaping up to be a big year for this neuropsychiatric disorder, and she also shared details about our recent partnership with Boehringer Ingelheim around a novel GPR52 agonist program for the treatment of schizophrenia   Listen here: https://lnkd.in/dc3dr73T #Schizophrenia #GPR52 #Neuroscience

We’re excited to share that we’ve dosed the first subject in our Phase 1 trial of HTL0033744, an EP4 receptor agonist for the treatment of Inflammatory Bowel Disease (#IBD). HTL’744 aims to address the significant unmet need of people with IBD that do not achieve satisfactory disease control. Read more here: https://lnkd.in/eqKcZciR